A Retrospective Analysis of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy for Advanced or Recurrent Non‐small Cell Lung Cancer
THORACIC CANCER（2021）
Key words
adverse event,combination therapy,immune checkpoint inhibitor,overall survival,treatment discontinuation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined